BIOMAT Database Logo BIOMAT Database Logo

[Treatment of hyperprolactinemias by pergolide mesylate]. 1987

S Loison, and G Turpin, and H Scherrer, and J L de Gennes

UI MeSH Term Description Entries
D006966 Hyperprolactinemia Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8) Prolactin Hypersecretion Syndrome,Prolactin, Inappropriate Secretion,Hyperprolactinaemia,Inappropriate Prolactin Secretion,Inappropriate Prolactin Secretion Syndrome,Hyperprolactinemias,Hypersecretion Syndrome, Prolactin,Inappropriate Secretion Prolactin,Prolactin Secretion, Inappropriate,Secretion Prolactin, Inappropriate,Secretion, Inappropriate Prolactin,Syndrome, Prolactin Hypersecretion
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010479 Pergolide A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES. Celance,LY-127,809,LY-127809,Parkotil,Pergolide Mesylate,Permax,Pharken,LY127,809,LY127809,Mesylate, Pergolide
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S Loison, and G Turpin, and H Scherrer, and J L de Gennes
Pergolide mesylate treatment of cocaine withdrawal.
January 1991, The Journal of clinical psychiatry,
S Loison, and G Turpin, and H Scherrer, and J L de Gennes
Pergolide mesylate in Parkinson's disease treatment.
January 1995, Journal of neural transmission. Supplementum,
S Loison, and G Turpin, and H Scherrer, and J L de Gennes
[Cutaneous vasculitis during pergolide mesylate treatment].
September 2002, La Revue de medecine interne,
S Loison, and G Turpin, and H Scherrer, and J L de Gennes
Pergolide mesylate form II.
October 2003, Acta crystallographica. Section C, Crystal structure communications,
S Loison, and G Turpin, and H Scherrer, and J L de Gennes
Psychoactive properties of pergolide mesylate.
January 1995, Journal of psychoactive drugs,
S Loison, and G Turpin, and H Scherrer, and J L de Gennes
[Sleep attacks and pergolide mesylate].
February 2001, Neurologia (Barcelona, Spain),
S Loison, and G Turpin, and H Scherrer, and J L de Gennes
Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.
April 1983, British medical journal (Clinical research ed.),
S Loison, and G Turpin, and H Scherrer, and J L de Gennes
Pergolide mesylate and idiopathic Parkinson disease.
October 1982, Neurology,
S Loison, and G Turpin, and H Scherrer, and J L de Gennes
The long-acting dopamine agonist pergolide mesylate for treatment of hyperprolactinaemia.
January 1984, Acta Europaea fertilitatis,
S Loison, and G Turpin, and H Scherrer, and J L de Gennes
Pergolide mesylate. Adverse events occurring in the treatment of cocaine dependence.
January 1997, The American journal on addictions,
Copied contents to your clipboard!